Jefferies Maintains Buy on Vaxcyte, Raises Price Target to $129
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Roger Song maintains a Buy rating on Vaxcyte (NASDAQ:PCVX) and raises the price target from $108 to $129.
September 03, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Roger Song has reaffirmed a Buy rating on Vaxcyte and increased the price target from $108 to $129, indicating confidence in the company's future performance.
The increase in the price target from $108 to $129 by Jefferies suggests a positive outlook on Vaxcyte's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100